Analysis of Anticoagulation Therapy and Anticoagulation-Related Outcomes Among Asian Patients After Mechanical Valve Replacement

被引:18
作者
Huang, Jo-Ting [1 ]
Chan, Yi-Hsin [2 ]
Wu, Victor Chien-Chia [2 ]
Cheng, Yu-Ting [2 ,3 ,4 ]
Chen, Dong-Yi
Lin, Chia-Pin [2 ]
Hung, Kuo-Chun [2 ]
Chang, Shang-Hung [2 ]
Chu, Pao-Hsien [2 ]
Chou, An-Hsun [5 ]
Chen, Shao-Wei [3 ,4 ]
机构
[1] Chang Gung Univ, Coll Med, Dept Educ, Chang Gung Mem Hosp, Taoyuan, Taiwan
[2] Chang Gung Univ, Linkou Med Ctr, Dept Cardiol, Chang Gung Mem Hosp, Taoyuan, Taiwan
[3] Chang Gung Univ, Linkou Med Ctr, Dept Surg, Chang Gung Mem Hosp, Taoyuan, Taiwan
[4] Chang Gung Mem Hosp, Linkou Med Ctr, Ctr Big Data Analyt & Stat, Taoyuan, Taiwan
[5] Chang Gung Univ, Dept Anesthesiol, Chang Gung Mem Hosp, Linkou Med Ctr, Taoyuan, Taiwan
关键词
AORTIC-VALVE; RESEARCH DATABASE; WARFARIN THERAPY; INTENSITY; VALIDATION; EVENTS; STROKE;
D O I
10.1001/jamanetworkopen.2021.46026
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE Current international normalized ratio (INR) guidelines are based on trials involving European and US populations. To our knowledge, no adequate study involving Asian patients has been conducted to date. OBJECTIVE To evaluate the association between INR and anticoagulation-related outcomes in an Asian population after mechanical aortic valve replacement (AVR) or mitral VR (MVR). DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study was conducted between 2001 and 2018, with follow-up until December 31, 2018, among patients who underwent AVR, MVR, or combined AVR-MVR at 3 medical centers and 4 regional hospitals and contributed electronic medical records to the Chang Gung Research Database. Exclusion criteria were missing demographic characteristics, younger than 20 years, fewer than 2 INR records, and having died during the hospitalization of the index surgery. MAIN OUTCOMES AND MEASURES Bleeding and thromboembolic complications were analyzed. The possibility of nonlinearity and cutoff potential for the INR were explored using a logistic regression model, which considered the INR a restricted cubic spline (RCS) variable. RESULTS The study population consisted of 900 patients, with 525 (58.3%) men and 375 (41.7%) women and a mean (SD) age of 52.0 (12.5) years. Overall, 474 (52.7%) received AVR alone, 329 (36.6%) received MVR alone, and 97 (10.8%) received combined AVR-MVR. All patients had at least 2 INR examinations after discharge, providing 16 676 INR records for the AVR group and 18 207 for the MVR and combined AVR-MVR groups. In the AVR group, the RCS model showed that higher risks of composite thromboembolic events were associated with an INR of less than 2.0 or greater than 2.6 vs an INR of 2.0, and a higher risk of bleeding events was associated with an INR of less than 1.8 or greater than 2.4 vs an INR of 2.0. When treating the INR as a categorical variable, the risk of composite thromboembolic and composite bleeding events was significantly higher among patients with IN Rs less than 1.5 (adjusted odds ratio [aOR], 2.55; 95% CI, 1.37-4.73) and with INRs of 3.0 or greater (aOR, 3.48; 95% CI, 1.95-6.23) vs those with IN Rs between 2.0 and 2.5.In the MVR and combined AVR-MVR groups, higher risks of composite thromboembolic events were associated with an INR of less than 2.1 or greater than 2.7 vs an INR of 2.5, and a higher risk of bleeding events was associated with an INR of less than 2.1 or greater than 2.8 vs an I NR of 2.5. When treating the INR as a categorical variable, the risk of a composite bleeding events was significantly higher among patients with IN Rs of 3.5 or greater (aOR, 2.25; 95% CI, 1.35-3.76) vs those with IN Rs between 2.5 and 3.0. CONCLUSIONS AND RELEVANCE Among Asian patients in this study, the incidence of thromboembolic events in the MVR group with IN Rs in the range of 2.0 to 2.5 was not significantly higher than that among those with IN Rs in the range of 2.5 to 3.0; in the AVR group, the incidence for those with INRs in 1.5 to 2.0 range was not significantly higher than for those with INRs in the range of 2.0 to 2.5.
引用
收藏
页数:13
相关论文
共 30 条
[1]   AREVA: Multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves [J].
Acar, J ;
Iung, B ;
Boissel, JP ;
Samama, MM ;
Michel, PL ;
Teppe, JP ;
Pony, JC ;
LeBreton, H ;
Thomas, D ;
Isnard, R ;
deGevigney, G ;
Viguier, E ;
Sfihi, A ;
Hanania, G ;
Ghannem, M ;
Mirode, A ;
Nemoz, C ;
Bossard, N ;
Rolland, C ;
Lion, L ;
Marsault, C ;
Ferroir, JP ;
Conard, J ;
Laborde, JP ;
Logeais, Y ;
Delahaye, JP ;
Guerin, F ;
Lainee, R ;
Lesbre, JP .
CIRCULATION, 1996, 94 (09) :2107-2112
[2]   Mechanical Prosthetic Heart Valve Thrombosis in a Patient Receiving Rivaroxaban [J].
Carvalho Silva, Daniela Marisa ;
Braga, Ana ;
de Jesus, Ilidio ;
Neves, Jose .
CARDIOLOGY, 2019, 143 (3-4) :116-120
[3]   Propensity Score Matched Analysis of Mechanical vs. Bioprosthetic Valve Replacement in Patients With Previous Stroke [J].
Chen, Shao-Wei ;
Wu, Victor Chien-Chia ;
Lin, Yu-Sheng ;
Chen, Ching-Chang ;
Chen, Dong-Yi ;
Chang, Chih-Hsiang ;
Chu, Pao-Hsien ;
Ting, Pei-Chi ;
Chou, An-Hsun ;
Chen, Tien-Hsing .
CIRCULATION JOURNAL, 2018, 82 (08) :2041-+
[4]   Validation of Acute Myocardial Infarction Cases in the National Health Insurance Research Database in Taiwan [J].
Cheng, Ching-Lan ;
Lee, Cheng-Han ;
Chen, Po-Sheng ;
Li, Yi-Heng ;
Lin, Swu-Jane ;
Yang, Yea-Huei Kao .
JOURNAL OF EPIDEMIOLOGY, 2014, 24 (06) :500-507
[5]   The lowest effective intensity of prophylactic anticoagulation for patients with atrial fibrillation [J].
Cheung, CM ;
Tsoi, TH ;
Huang, CY .
CEREBROVASCULAR DISEASES, 2005, 20 (02) :114-119
[6]   Rivaroxaban Versus Warfarin in Patients with Mechanical Heart Valves: Open-Label, Proof-of-Concept trial-The RIWA study [J].
Duraes, Andre Rodrigues ;
Lima Bitar, Yasmin de Souza ;
Schonhofen, Igor Santos ;
Oliveira Travassos, Kethyren Santos ;
Pereira, Larissa Vitoria ;
Lima Filho, Jose Admirco ;
Gomes Neto, Mansueto ;
Aras Junior, Roque ;
Roever, Leonardo .
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2021, 21 (03) :363-371
[7]   Dabigatran versus Warfarin in Patients with Mechanical Heart Valves [J].
Eikelboom, John W. ;
Connolly, Stuart J. ;
Brueckmann, Martina ;
Granger, Christopher B. ;
Kappetein, Arie P. ;
Mack, Michael J. ;
Blatchford, Jon ;
Devenny, Kevin ;
Friedman, Jeffrey ;
Guiver, Kelly ;
Harper, Ruth ;
Khder, Yasser ;
Lobmeyer, Maximilian T. ;
Maas, Hugo ;
Voigt, Jens-Uwe ;
Simoons, Maarten L. ;
Van de Werf, Frans .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (13) :1206-1214
[8]  
GOHLKEBARWOLF C, 1995, EUR HEART J, V16, P1320
[9]   Mechanical or Biologic Prostheses for Aortic-Valve and Mitral-Valve Replacement [J].
Goldstone, Andrew B. ;
Chiu, Peter ;
Baiocchi, Michael ;
Lingala, Bharathi ;
Patrick, William L. ;
Fischbein, Michael P. ;
Woo, Y. Joseph .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (19) :1847-1857
[10]   Thromboembolic and bleeding complications following St. Jude medical valve replacement - Results of the German experience with low-intensity anticoagulation study [J].
Hering, D ;
Piper, C ;
Bergemann, R ;
Hillenbach, C ;
Dahm, A ;
Huth, C ;
Horstkotte, D .
CHEST, 2005, 127 (01) :53-59